U
LSTA icon

UBS’s Lisata Therapeutics LSTA Stock Holding History

UBS’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-7
Closed -$9K – 10591
2013
Q3 		$9K Buy
+7
New +$7.77K ﹤0.01% 8914

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
TFO
Tarbox Family Office Newport Beach, California $616M AUM 18.34% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

UBS's LSTA Position: Q3 2014 in Review

UBS reduced its Lisata Therapeutics (LSTA) stake by 89% in Q3 2014, selling an estimated $41.1K and leaving 6 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #9457.

UBS first reported a position in LSTA in Q2 2013 and has held it in 6 quarters since. The position peaked at $451K in Q1 2014. 50 funds tracked by Wall St. Rank hold LSTA as of Q3 2014.

  • UBS held 6 shares of Lisata Therapeutics worth $5K as of Q3 2014.
  • UBS sold 47 Lisata Therapeutics shares in Q3 2014, an estimated $41.1K.
  • Lisata Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9457 holding.
  • UBS first reported a position in Lisata Therapeutics in Q2 2013 and has held it in 6 quarters since.
  • UBS's Lisata Therapeutics position peaked at $451K in Q1 2014.
  • 50 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.